BRPI0502657B8 - pharmacological use of cyclodextrin-au-thiol-derived nanoparticles / hydrophobic compound as antitumor, antibacterial, antiviral and/or antiparasitic, its process of obtaining and its formulation - Google Patents
pharmacological use of cyclodextrin-au-thiol-derived nanoparticles / hydrophobic compound as antitumor, antibacterial, antiviral and/or antiparasitic, its process of obtaining and its formulationInfo
- Publication number
- BRPI0502657B8 BRPI0502657B8 BRPI0502657A BRPI0502657A BRPI0502657B8 BR PI0502657 B8 BRPI0502657 B8 BR PI0502657B8 BR PI0502657 A BRPI0502657 A BR PI0502657A BR PI0502657 A BRPI0502657 A BR PI0502657A BR PI0502657 B8 BRPI0502657 B8 BR PI0502657B8
- Authority
- BR
- Brazil
- Prior art keywords
- violacein
- beta
- cyclodextrin
- antitumor
- antibacterial
- Prior art date
Links
Abstract
uso farmacológico de nanopartículas ciclodextrina-au-tiolderivada/composto hidrofóbico como antitumoral, antibacteriano, antiviral e/ou antiparasitário e seu processo de obtenção e sua formulação. esta invenção descreve a produção e formulação da violaceína encapsulada em (beta)-ciclodextrina conjugada a uma nanopartícula de ouro através de um ditiol como a mono[6-deoxi-6-[(mercaptohexametileno)tio]]-(beta)-cyclodextrina-au (au-s(ch2)6-s-(beta)-cd) e sua citoxicidade in vitro em duas diferentes culturas de células (células leucêmicas hl60 e fibroblastos v79). o complexo sem a violaceína (au-s(ch2)6-s-(beta)-cd) não apresentou citotoxicidade nas linhagens estudadas na concentração usada. os resultados indicam que a complexação da violaceína com au-s(ch2)6-s-(beta)-cd manteve o efeito citotóxico nas células leucêmicas e reduzem a toxicidade em v79 comparada a violaceína livre. estes dados indicam que o complexo au-s(ch2)6-s-(beta)-cd/violaceína pode ser usado para melhorar as propriedades farmacológicas da violaceína, principalmente as antitumorais, já que o complexo pode manter a atividade antileucêmica e reduzir significativamente a toxicidade em moléculas normais. adicionalmente, estas propriedades podem exercer um importante papel em tratamentos antibacterianos e antiparasitárias e o composto au-s(ch2)6-s-(beta)-cd pode ser usado para transporte de grupos químicos semelhantes em tamanho a violaceína sem restrição da doença a ser tratada.pharmacological use of cyclodextrin-au-thiolderivate/hydrophobic compound nanoparticles as antitumor, antibacterial, antiviral and/or antiparasitic and its process of obtaining and its formulation. this invention describes the production and formulation of violacein encapsulated in (beta)-cyclodextrin conjugated to a gold nanoparticle through a dithiol such as mono[6-deoxy-6-[(mercaptohexamethylene)thio]]-(beta)-cyclodextrin- au (au-s(ch2)6-s-(beta)-cd) and its cytotoxicity in vitro in two different cell cultures (hl60 leukemic cells and v79 fibroblasts). the complex without violacein (au-s(ch2)6-s-(beta)-cd) did not show cytotoxicity in the strains studied at the concentration used. the results indicate that the complexation of violacein with au-s(ch2)6-s-(beta)-cd maintained the cytotoxic effect on leukemic cells and reduced toxicity in v79 compared to free violacein. these data indicate that the au-s(ch2)6-s-(beta)-cd/violacein complex can be used to improve the pharmacological properties of violacein, especially the antitumor ones, as the complex can maintain the antileukemic activity and significantly reduce the toxicity in normal molecules. additionally, these properties can play an important role in antibacterial and antiparasitic treatments and the compound au-s(ch2)6-s-(beta)-cd can be used to transport chemical groups similar in size to violacein without disease restriction to be treated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0502657A BRPI0502657B8 (en) | 2005-06-28 | 2005-06-28 | pharmacological use of cyclodextrin-au-thiol-derived nanoparticles / hydrophobic compound as antitumor, antibacterial, antiviral and/or antiparasitic, its process of obtaining and its formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0502657A BRPI0502657B8 (en) | 2005-06-28 | 2005-06-28 | pharmacological use of cyclodextrin-au-thiol-derived nanoparticles / hydrophobic compound as antitumor, antibacterial, antiviral and/or antiparasitic, its process of obtaining and its formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0502657A BRPI0502657A (en) | 2007-05-08 |
| BRPI0502657B1 BRPI0502657B1 (en) | 2019-05-07 |
| BRPI0502657B8 true BRPI0502657B8 (en) | 2021-05-25 |
Family
ID=38007743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0502657A BRPI0502657B8 (en) | 2005-06-28 | 2005-06-28 | pharmacological use of cyclodextrin-au-thiol-derived nanoparticles / hydrophobic compound as antitumor, antibacterial, antiviral and/or antiparasitic, its process of obtaining and its formulation |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRPI0502657B8 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011110932A1 (en) | 2010-03-12 | 2011-09-15 | Council Of Scientific & Industrial Research | Process for the production of violacein and its derivative deoxyviolacein containing bioactive pigment from chromobacterium sp. (mtcc 5522) |
-
2005
- 2005-06-28 BR BRPI0502657A patent/BRPI0502657B8/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0502657B1 (en) | 2019-05-07 |
| BRPI0502657A (en) | 2007-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mei et al. | Two-dimensional nanomaterials beyond graphene for antibacterial applications: current progress and future perspectives | |
| Konur | Recent citation classics in antimicrobial nanobiomaterials | |
| Chen et al. | Facile and green reduction of covalently PEGylated nanographene oxide via a ‘water-only’route for high-efficiency photothermal therapy | |
| BRPI0905080B8 (en) | sulfoalkyl ether cyclodextrin (sae-cd) composition, processes for preparing a sulfoalkyl ether cyclodextrin (sae-cd) composition, process for preparing a composition and product | |
| Ji et al. | Nitrogen and sulfur co-doped carbon nanodots in living EA. hy926 and A549 cells: Oxidative stress effect and mitochondria targeting | |
| Sharma et al. | Green synthesis of nanoparticles and its key applications in various sectors | |
| BRPI0502657B8 (en) | pharmacological use of cyclodextrin-au-thiol-derived nanoparticles / hydrophobic compound as antitumor, antibacterial, antiviral and/or antiparasitic, its process of obtaining and its formulation | |
| Beltrán-Partida et al. | Synthesis, characterization, and in situ antifungal and cytotoxicity evaluation of ascorbic acid-capped copper nanoparticles | |
| Zou et al. | Biomineralization-inspired synthesis of cerium-doped carbonaceous nanoparticles for highly hydroxyl radical scavenging activity | |
| Guo et al. | Self-enhanced photothermal-chemodynamic antibacterial agents for synergistic anti-infective therapy | |
| Teixeira et al. | Cyclodextrin modulates the cytotoxic effects of chlorhexidine on microrganisms and cells in vitro | |
| Kithiyon et al. | Efficacy of mycosynthesised AgNPs from Earliella scabrosa as an in vitro antibacterial and wound healing agent | |
| Biswas et al. | Wet chemical development of CuO/GO nanocomposites: its augmented antimicrobial, antioxidant, and anticancerous activity | |
| Govindasamy et al. | Phytochemicals, biodegradation, cytocompatibility and wound healing profiles of chitosan film embedded green synthesized antibacterial ZnO/CuO nanocomposite | |
| Cao et al. | Blood-brain barrier permeable and multi-stimuli responsive nanoplatform for orthotopic glioma inhibition by synergistic enhanced chemo-/chemodynamic/photothermal/starvation therapy | |
| Lee et al. | Review of the usability of cyclodextrin as a cosmetic ingredient | |
| Seitak et al. | 2D MXenes for controlled releases of therapeutic proteins | |
| Kolathupalayam Shanmugam et al. | Curcumin loaded gold nanoparticles–chitosan/sodium alginate nanocomposite for nanotheranostic applications | |
| Bajad et al. | A systematic review of carbohydrate-based bioactive molecules for Alzheimer’s disease | |
| Menikpurage et al. | Antioxidant activity and cytotoxicity of the edible mushroom, Pleurotus cystidiosus against Hep-2 carcinoma cells | |
| Krishnamoorthy et al. | Green synthesis and evaluation of anti-microbial, antioxidant, anti-inflammatory, and anti-diabetic activities of silver nanoparticles from Argyreia nervosa leaf extract: an invitro study | |
| Schutt et al. | Drug delivery nanoparticles with locally tunable toxicity made entirely from a light-activatable prodrug of doxorubicin | |
| Li et al. | Single-wall carbon nanohorns inhibited activation of microglia induced by lipopolysaccharide through blocking of Sirt3 | |
| Jabri et al. | Antibacterial Properties of Ethacridine Lactate and Sulfmethoxazole Loaded Functionalized Graphene Oxide Nanocomposites | |
| Parihar et al. | To review on the pharmacology of the leaf extract of Catharanthus roseus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |